IRWD
Ironwood Pharmaceuticals Inc. Class A Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.708
Kõrge
$0.708
Madal
$0.708
Maht
0.85M
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika
Seotud uudised
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel syndrome with constipation (IBS-C); first completed Phase III
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.